What it sells
Pioneering Breast Cancer Diagnostics for a Healthier Tomorrow
Business model breakdown
Buyer: who owns the budget?
UnverifiedHospital oncology/pathology departments and multidisciplinary teams (clinician-ordered in vitro diagnostic).
Trigger: what makes them buy now?
Post-surgery decision on recurrence risk and whether to escalate treatment.
Workflow: what inputs become what output?
Tumour tissue analysed by infrared spectrometry to produce Digistain Index, combined with clinicopathological features in a validated multivariate model to give a Digistain Prognostic Score for MDT discussion.
Economics: what it saves and how it charges
UnverifiedPer-test diagnostic service/IVD; claims validation in a retrospective cohort of 801 patients with 12.7 years median follow-up.
Distribution: how it reaches customers
Clinician-facing, contact-led; UKCA-marked, MHRA registered.
Funding history and coverage
| Round date | Stage | Amount | Investors | Source |
|---|---|---|---|---|
| — | Y Combinator Summer 2021 | — | Y Combinator | ycombinator.com |
Profiles summarize public reporting and company websites. Business-model notes are MaxBC's reading of that material, not confirmed facts; unknowns are left blank rather than guessed. Updated 2026-10-12.